Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Skin biopsy in early disease showing apoptotic keratinocytes in the epidermis and in more advanced disease necrosis of the entire epidermis~* Epidermal detachment or erythematous to purpuric macules involving more than 10% of body surface area in addition to involvement of the oropharynx; there may be further involvement of other mucosal surfaces, ie. conjunctivae, gastrointestinal tract, respiratory and genitourinary epithelia~* Age of 18 years old or older~* The patient is expected to survive longer than 48 hours~Exclusion Criteria:~* Skin detachment above 90% of the body surface area~* Skin detachment has not progressed during the previous 48 hours~* A positive serum pregnancy test~* Age \< 18 years old~* Known hematologic or solid organ malignancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Palifermin (Type: EXPERIMENTAL): Palifermin 60 micrograms/kg/day IV for 3 consecutive days

Based on this trial design, predict the completion outcome and termination type (if applicable).